A paradigm shift in cancer care
ChemoTech utilizes a patented treatment technology platform for human cancer care.
ChemoTech utilizes a patented treatment technology platform for human cancer care. Tumour Specific Electroporation™ (TSE) is designed to enhance the local effect of anti-cancer drugs. By using dynamic electrical currents, the TSE technology helps the treating physicians to avoids high currents to limiting unnecessary destruction of healthy surrounding tissue and reduces side effects.
ChemoTech is dedicated to developing and commercialising innovative and cost-effective technologies for the treatment of tumours. Our goal is to provide physicians with new treatment possibilities for patients whose tumours are difficult to treat with conventional methods.
TSE uses controlled, tumour-specific electrical stimulation to increase the uptake of anti-cancer drugs in the treated area. The technology is designed to promote controlled tumour cell death while reducing unnecessary tissue destruction and preserving surrounding healthy tissue.
Our initial commercial focus for superficial tumours is India and selected markets in India, Asia, the Middle East and Africa, where there is a significant need for accessible and cost-effective cancer treatment technologies.
In parallel, ChemoTech is advancing the clinical development of TSE for selected deep-seated tumours through collaborations with physicians, researchers and clinical institutions.
IQwave™ is ChemoTech’s CE-marked dynamic electroporation system based on the TSE technology platform. It is designed to deliver tumour-specific electrical stimulation in combination with a very low dose of anti-cancer drugs for the treatment of solid tumours.
TSE technology is well suited to treating tumours in sensitive areas where surgery is not possible, such as head and neck tumours. It can be used as primary treatment or combined with surgery to shrink the tumour and/or treat unclean margins. The technology can also be used before surgery to facilitate surgery, during radiotherapy, and for palliative care.
In summary, TSE:
There is growing evidence that TSE using IQwave™ and the published D-EECT protocol enhances the efficacy and safety of electrochemotherapy (ECT) approaches to the treatment of solid tumours.
TSE increases the effect of chemotherapy even at a lower dose, compared to traditional treatments, and enables the treatment of tumours that normally do not respond to chemotherapy. TSE delivers a carefully monitored energy to minimize tissue death while maximizing treatment efficacy and activating the immune system through apoptosis and release of a specific tumour antigen; an area that we will place great emphasis on in future clinical development.
Adapting and calibrating the technology, to be powerful enough to treat the tumour without generating destruction and ablation of healthy tissue is central to the TSE technology.
Get in touch
Are you interested in our products?
Our team is here to help with any questions about our products, patents or anything else you may need help with.
This website uses cookies. If you continue to browse the website, you agree to the use of cookies.